drugset
Drugs / CP-866,087
last change Oct 2008 re-read 3 minutes ago

CP-866,087

Small molecule targets OPRM1 via inhibition

Developed for
alcohol dependence · obesity disorder · physiological sexual disorder
Investigated by
Pfizer

Trials 3

today NCT00482664 · Ph 2 NCT00479492 · Ph 2 NCT00147576 · Ph 2
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00482664 Jul 2007 → Sep 2008 physiological sexual disorder Pfizer Completed No outcome recorded
Phase 2 NCT00479492 Jun 2007 → Jan 2008 obesity disorder Pfizer Completed No outcome recorded
Phase 2 NCT00147576 Dec 2003 → Dec 2004 alcohol dependence Pfizer Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as CP-866,087 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479492 ↗
2

NCT00147576 ↗

NCT00482664 ↗
Action Inhibit “Mu opioid receptor antagonist” CHEMBL3219616 ↗
Modality Small molecule — CHEMBL3219616 ↗
Target OPRM1 “Mu opioid receptor antagonist” CHEMBL3219616 ↗